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ABSTRACT

ARTICLE HISTORY

Osteoporosis is associated with an increased risk of pathologic fractures; however, most
patients do not receive diagnosis and adequate treatment. The aim of our study was to
compare the yearly trends of osteoporosis and osteoporotic fragility fractures in the USA (US)
inpatients.
We used National (Nationwide) Inpatient Sample database to identify adults ≥18 years
with diagnoses of osteoporosis and pathologic fractures and excluded pathologic fractures
due to other etiologies. We then studied the annual trends, in terms of annual percentage
change (APC), of osteoporosis and osteoporotic fractures.
Among overall hospitalizations, osteoporosis was noted to have an increasing trend from 2000
to 2009 (APC = 5.81, p < 0.05) with a decline thereafter (APC = – 3.88, p < 0.05). In contrast,
osteoporotic fracture showed an initial downward trend from 2000 to 2010 (APC = −7.31, p < 0.05),
followed by a slowly rising trend (APC = 2.0, p = NS).
The initially increasing trend of osteoporosis was followed by a decreasing trend thereafter. In contrast, there was a halt in a previously declining trend of osteoporotic fracture.
Potential explanations include inadequate screening and treatment per guidelines along with
decreasing patient compliance. In conclusion, primary and secondary prevention measures
for osteoporosis have been underutilized by both physicians and patients alike.
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1. Background
Osteoporosis is a systemic bone disease characterized
by low bone mass and skeletal fragility. Osteoporosis
patients are at a risk of subsequent pathologic fractures leading to morbidity, mortality, and poor life
quality. Osteoporosis prevalence continues to
increase among older Americans and is a major
cause of disability. Despite all the available treatment
options, most patients do not receive early diagnosis
and adequate treatment [1, 2]. The aim of our study
was to assess the prevalence of osteoporosis and
osteoporotic fragility fractures among inpatients.

2. Methods
We used National (Nationwide) Inpatient Sample (NIS)
database for years 2000–2014 to select adult hospitalizations (≥18 years of age). Information on T-scores was
not available in the database, and the diagnoses of
osteoporosis and pathologic fractures were based on
ICD-9 codes 733.0x and 733.1x, respectively. We
excluded pathologic fractures associated with diagnoses
other than osteoporosis, including osteomyelitis (acute,
chronic, and unspecified), periostitis, poliomyelitis,
other bone infections, all neoplasms, osteitis deformans,
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renal osteodystrophy, rickets, and osteomalacia, all of
which were also identified based on ICD-9 codes used
for billing purposes.
We studied the trend of osteoporosis and osteoporotic fractures in inpatients. Differences in annual
trends were analyzed in terms of annual percentage
change (APC), calculated using the Joinpoint regression analysis statistical software. APC is a way to
characterize disease trends over a specified time interval in which the disease rates are assumed to change
at a constant percentage of the rate of the
previous year. The Joinpoint software takes trend
data, and based on the maximum number of joinpoints supplied by the user, fits the data into segments, enabling the users to assess if the apparent
change in trend is statistically significant [3].

3. Results
A sample of 2,975,120 (weighted national estimate,
N = 14,245,268) osteoporosis and 175,383 (weighted,
N = 838,977) osteoporotic fragility fractures were
identified from the years 2000–2014. Among overall
hospitalizations, osteoporosis was noted to have an
increasing trend from 2000 to 2009 (APC = 5.81,
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% osteoporosis among overall hospitalizations

% fragility # among hospitalizations with osteoporosis

APC: (2000 - 2009) 5.81, p<0.05
APC: (2009-2014) - 3.88, p <0.05

APC: (2000 - 2010) -7.31 , p<0.05
APC: (2010-2014) 2.0 , p NS

12
9.92
10

8.85

8.1
7.26

8

7.03

6.2
6

5.78

5.57

5.2

4.93

4.53

4.57

4.67

4.6

4.86

3.34

3.17

3.09

2012

2013

2014

4
2
0

2.12

2.38

2.6

2.73

2.82

2000

2001

2002

2003

2004

3.15

3.14

3.31

3.52

3.6

3.63

3.65

2005

2006

2007

2008

2009

2010

2011

Figure 1. Trends of Osteoporosis and Fragility Fracture Hospitalizations (2000-2014)

p < 0.05) with a decline thereafter (APC = – 3.88,
p < 0.05) (Figure 1). In contrast, osteoporotic fragility fractures among overall hospitalizations showed
an initial downward trend from 2000 to 2010 (APC
= −7.31, p < 0.05), followed by a nonsignificant but
a slowly rising trend thereafter (APC = 2.0, p = NS)
(Figure 1).

4. Discussion and conclusion
In our study of hospitalized patients, the initially
increasing trend of osteoporosis prevalence was followed by a decreasing trend thereafter. On the other
hand, there was a halt in previously declining osteoporotic fragility fractures. It is important to note that, in
the latter half of the study period, while osteoporosis
prevalence was noted to be decreasing, the prevalence of
fragility fractures was increasing inversely. Whether the
noted decrease in osteoporosis represents a true decline
due to better prevention, or simply a decline in screening and subsequent detection, is not certain. However, if
the decreased osteoporosis prevalence was a result of
better preventative measures, one would expect the
number of osteoporotic fragility fractures to decrease
as well. Another study by Lewiecki et al. to assess the hip
fracture rates using Medicare claims data from 2002 to
2015 also noted that hip fracture rates declined from
2002 to 2012 and then plateaued at higher than projected levels from 2013 onward, with resultant increase
in over 11,000 hip fractures [4].
A study by King et al. noted plateauing of dualenergy x-ray absorptiometry (DEXA) testing in
2007–2009 and suggested that the noted trend could
partly be attributed to lowering of Medicare reimbursement for DEXA scans starting in 2007, resulting in
fewer patients being screened and treated for osteoporosis [5]. A similar phenomenon might explain our

study results, with the noted decrease in osteoporosis
actually being related to decreased detection rates
rather than a true decrease in prevalence, subsequently
leading to increasing fracture trend.
Another explanation for noted results could be that
the physicians are not adequately screening and treating
for osteoporosis per guidelines. Current standard
screening recommendations for osteoporosis, per the
USA Preventive Services Task Force (USPSTF), include
all women >65 and younger women with risk factors,
using bone density screening [6]. The National
Osteoporosis Foundation (NOF) makes the above
recommendations as well, but also includes the recommendation for screening men over 70 years, men 50–69
years with risk factors, and all patients with fragility
fractures above 50 years [7]. Although we have these
clear guidelines for screening for osteoporosis with
DEXA, only about 26.3% and 16.4% women aged
65–79 years and 80+ years, respectively, were found to
receive their screening DEXA prior to their first hip
fracture [8]. Even lesser percentage of patients (~23%)
had recommended screening for secondary prevention
following a fragility fracture, even when over 80% of
them had an office visit within 12 months postfracture
[8–11]. Additionally, most women who have fractures
do not receive treatment for osteoporosis [8,12,13].
A study by Freedman et al. showed that only about
24% of postmenopausal women who sustained a distal
radial fracture underwent either diagnosis or
a treatment of osteoporosis. Also, only a 3% increase
in antiosteoporotic medication prescribing in the periods before and after fracture was noted, suggesting that
physicians may have overlooked fractures as sentinel
events for osteoporosis detection [12,14].
The other major hindrance to treatment is patient
compliance, with a majority of patients breaking from
therapy, with only a quarter of patients achieving
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an year without breaking osteoporosis therapy [15–17].
A study noted that the treatment rates for osteoporosis
decreased steadily and significantly over time: from
23.8% (2001–2002) to 15.9% (2007–2009) for women
and from 10.6% (2001–2002) to 8.5% (2007–2009) for
men [10]. Zoledronic acid, oral bisphosphonates, denosumab, teriparatide, and raloxifene have all been shown
to significantly lower fracture rates [18]. However,
there was a significant decline in the number of prescriptions written for oral bisphosphonates beginning
in 2007–2008 and IV bisphosphonates from 2010,
coinciding with a spike in internet search for alendronates between 2006 and 2007 following media reports
of safety concerns [19,20]. However, it could as well
have been from the availability of alternate treatment
options. While some studies suggest that the rise in
fragility fracture trend could be related to decreased use
of hormone replacement therapy after the Women’s
Health Initiative trial was published [21], the noted
increase of fractures among men makes this a less likely
explanation [22].
Hence, it would not be unreasonable to state that
the primary and secondary prevention measures for
osteoporosis have been underutilized by both physicians and patients, although several possibilities exist
for prevention. More so, bone fragility is thought of
only after the onset of fragility fractures, and even
then, the management is often suboptimal.
Awareness of this will help increase physician prescribing practices and patient compliance.

5. Strengths and limitations
The major strength of our study is a large sample size
provided by the national database. However, a major
limitation is that the database used only provides data
for inpatients. The actual rate of osteoporosis is likely
higher than that found in this study as it does not
account for the outpatient setting. Also, the data we
observed were only until 2014. The newer medications
such as teriparatide and denosumab were not approved
for osteoporosis by the FDA until 2009/2010 and perhaps the effect of the newer agents is yet to be seen.
Further studies need to be done in order to determine
the cause of the slowly rising trend of osteoporotic
fragility fractures to best determine appropriate methods for prevention.
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